Apotex’ Apobiologix biosimilars unit says it “looks forward to further expansion of the portfolio to ensure we continue to support patient needs,” after launching the Bambevi (bevacizumab) biosimilar across Canada, the company’s “first oncology therapeutic treatment.”
In late September Apotex announced Health Canada approval for the biosimilar to Avastin, a product of the company’s strategic partnership with Spanish
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?